---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003587"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:55:49.464804+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025

## Summary
- Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.
- ACESOT-1051 trial of WEE1 inhibitor APR-1051 enrolling Cohort 5 (70 mg); open-label data expected H2 2025.
- ABOYA-119 trial of ATR inhibitor ATRN-119 evaluating BID dosing at Dose Level 7; dose escalation completion H2 2025.
- Employment agreement amended for officer John P. Hamill: severance extended to 12 months (18 months post-change-of-control).
- R&D expense increased to $9.4M for FY2024 from $7.6M, driven by trial costs and personnel.

## SEC filing metadata
- accession: 0001558370-25-003587
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/0001558370-25-003587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/apre-20250325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003587
- JSON: https://secwatch.observer/filing/0001558370-25-003587.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.